( Nasdaq : OREX ) , a biopharmaceutical company focused on the treatment of obesity , today announced positive secondary findings from the first of four Phase 3 trials of its lead investigational product Contrave ( R ) ( naltrexone sustained release ( SR ) / bupropion SR ) . These data were presented in one oral and two poster presentations at the American Diabetes Association 's ( ADA ) 69th Scientific Sessions in New Orleans , Louisiana .